Samuel Enrique Olivares Mundo

Samuel Enrique Olivares Mundo

Auto-generated profile, based on publicly available information

Samuel Enrique Olivares Mundo

Department of Psychiatry, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, México

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2023 in Psychiatry Investigation
Verified
Journal Article
Open access
PDF file
EUErasmo Saucedo Uribe
Erasmo Saucedo Uribe
SMSamuel Enrique Olivares Mundo
Samuel Enrique Olivares Mundo
RGRaul Ricardo Medrano Garza
Raul Ricardo Medrano Garza
FGFernando Diaz Gonzalez-Colmenero
Fernando Diaz Gonzalez-Colmenero
LSLorena Martinez Sanchez
Lorena Martinez Sanchez
SRSandra Sabrina Rojo-Garza
Sandra Sabrina Rojo-Garza
Objective To find the safety of long-acting injectable antipsychotics (LAIs) compared to each other, and/or placebo in the treatment of schizophrenia (SCZ) and/or schizoaffective disorder (SZA).Methods We performed a systematic review and a network meta-analysis of randomized controlled trials (RCTs) comparing the safety of LAIs versus other LAIs or placebo in adults diagnosed with SCZ or SZA. The primary outcomes were treatment emergent adverse events (TEAEs), serious treatment emergent adverse events (STEAEs), and deaths. The secondary outcomes included treatment discontinuations due to adverse events and all-cause discontinuations.Results Seventeen RCTs were included (n=7,908). There were no significant differences between LAIs and placebo in the risk of presenting TEAEs. LAIs had a significant lower risk of presenting STEAEs except for aripiprazole. No significant differences in deaths were found. LAIs showed a significant protective effect against all-cause discontinuation, except for haloperidol. Only aripiprazole had a significantly lower risk of treatment discontinuation due to adverse events.Conclusion We found no significant differences in the risk of presenting TEAEs between LAIs and placebo. The majority of LAIs had a significantly lower risk of presenting STEAEs than placebo. Development of international guidelines for the report of safety outcomes related to antipsychotics especially for LAIs in clinical trials could minimize report and interpretation biases and improve the accuracy of posterior meta-analysis.